Directif Partners with Epidauros to Market Its LabChip for Clinical Diagnostics

NEW YORK, March 23 (GenomeWeb News) - Directif GmbH and Epidauros Biotechnology have signed a co-development and co-marketing agreement for Directif's LabChip technology, the firms said today.

Epidauros, a provider of pharmacogenetic assays and services, will partner with Directif, a subsidiary of November AG based in Erlangen, Germany, to create "client-specific" applications for the LabChip technology, which offers automated analysis of nucleic acids for clinical diagnostic applications.

Bernried, Germany-based Epidauros said that it will market the LabChip to its established clientele of international pharmaceutical companies. Epidauros licensed a genetic polymorphism to Roche in November 2004 for use in its AmpliChip CYP450 test.

Financial details of the collaboration were not discussed.